Drug intelligence / Profile preview

ampicillin + sulbactam + clindamycin

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Intravenous, Intramuscular, Oral
01

Overview

This is a combination of three antibiotics: ampicillin (a semisynthetic penicillin), sulbactam (a beta-lactamase inhibitor), and clindamycin (a lincosamide antibiotic). The combination is sometimes used in clinical practice for treating complex infections requiring broad-spectrum coverage. **Ampicillin + sulbactam** works by: - Ampicillin binds to penicillin-binding proteins (PBPs) to inhibit bacterial cell wall synthesis - Sulbactam inhibits beta-lactamase enzymes that would otherwise break down ampicillin, extending coverage against potentially resistant bacteria - Together they provide enhanced activity against many gram-positive and gram-negative bacteria **Clindamycin** works by: - Inhibiting bacterial protein synthesis by binding to 23S RNA of the 50S subunit of the bacterial ribosome - Providing excellent coverage against anaerobic bacteria This combination may be used for treating complex infections such as aspiration pneumonia, lung abscesses, and certain surgical site infections.

02

Targets

Bacterial 50S ribosomal subunitβ-lactamasePBP1A (Penicillin-binding protein 1A)

Beyond the preview

Go deeper on ampicillin + sulbactam + clindamycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ampicillin + sulbactam + clindamycin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call